Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Opioid Stories

2012-11-12 08:26:39

SAN FRANCISCO, Nov. 12, 2012 /PRNewswire/ -- AstraZeneca today announced positive top-line results from two Phase III trials and one safety extension trial in patients with non-cancer related pain and opioid-induced constipation (OIC). These Phase III KODIAC trials evaluated the safety and efficacy of naloxegol, an oral peripherally-acting, mu-opioid receptor antagonist for the treatment of OIC, a common side effect of prescription opioids. KODIAC-04 and -05 are both multicenter, randomized,...

2012-11-08 12:27:47

BALTIMORE, Nov. 8, 2012 /PRNewswire/ -- Ameritox(SM), the nation's leader in medication monitoring solutions, today announced an upcoming symposium titled "Emerging Trends in Managing Opioid Abuse and Misuse: New Recommendations and Designer Drugs," to be held in conjunction with the third annual California Society of Interventional Pain Physicians (CASIPP) meeting in Newport Beach, Calif., on Nov. 10. The symposium will feature leading pain expert Daniel Bennett, M.D., medical director,...

2012-11-05 08:31:44

REDWOOD CITY, Calif., Nov. 5, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it has dosed the first subjects in a Phase 2, placebo-controlled, dose-finding study of its ARX-04 sufentanil NanoTab product candidate. This study will enroll approximately 100 patients following bunionectomy...

2012-10-31 11:25:43

CHICAGO, Oct. 31, 2012 /PRNewswire/ -- According to a presentation made at the recent annual meeting of the American Society of Anesthesiologists, preventable deaths in hospitals remain a major public health hazard worldwide. Frank J Overdyk, MD, Marieke Niesters, MD, Albert Dahan, MD, PhD, in their presentation, "Respiratory Depression: The Common Fatal Pathway for 'Non Fatal' Conditions", say: "Preventable deaths in hospitals remain a major public health hazard worldwide. Analysis of...

2012-10-19 07:23:21

CUMBERLAND, R.I., Oct. 19, 2012 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the presentation of a scientific poster titled "Alternate methods of oral administration for Oxycodone DETERx, a novel, extended-release, tamper-resistant opioid formulation" at the 2012 Annual Meeting of the American Association of Pharmaceutical Scientists, held in Chicago, Illinois from...

2012-10-15 07:28:27

RALEIGH, N.C., Oct. 15, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced the commercial launch of BREAKYL (fentanyl buccal film) in the European Union. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) BDSI's commercial partner for BREAKYL in the E.U. is Meda. Under the terms of its E.U. agreement with Meda, BDSI will now receive a final milestone payment of $2.5 million. BDSI will also receive a royalty on net sales of BREAKYL in the...

2012-10-13 04:04:32

IMPROVE trial compares the cost of care between a standard opioid-based regimen and an EXPAREL-based multimodal regimen for postsurgical pain management. Online (PRWEB) October 11, 2012 PARSIPPANY, N.J.-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced topline results from the first completed IMPROVE study in its prospective Phase 4 clinical program. The study was designed to compare the difference in three primary endpoints–cost, opioid consumption and hospital length of...

2012-10-09 04:00:35

The primary objective of this study is to evaluate the efficacy of a new drug compared with a placebo in opioid-experienced and opioid-naive subjects with moderate-to-severe Chronic Lower Back Pain. DeLand, Florida (PRWEB) October 08, 2012 Today, there isn´t a ℠one pill´ treatment that either treats or cures back pain. At best there is a multidisciplinary approach that uses a combination of medication and lifestyle changes that seem to work to a degree. In many cases...

2012-10-03 23:03:40

This study addressed a very serious issue in South Carolina: if a worker and doctor decided that narcotics should be taken, there was a 1 in 10 chance that the worker would still be taking narcotics 3 to 6 months later — a 25 percent higher risk than in the median state. CAMBRIDGE, MA (PRWEB) October 02, 2012 With opioid misuse a top public health problem in the United States, a new report by the Workers Compensation Research Institute (WCRI) showed that few physicians in South...

2012-10-03 23:03:34

This study will help public officials, employers, and other stakeholders understand as well as balance providing appropriate care to injured workers while reducing unnecessary risks to patients and costs to employers. Cambridge, MA (PRWEB) October 02, 2012 With opioid misuse a top public health problem in the United States, a new report by the Workers Compensation Research Institute (WCRI) showed that few physicians were following recommended treatment guidelines to prevent it. This...